Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agatolimod plus Erlotinib in advanced EGFR-positive NSCLC
NCT00321815Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2006
- Primary completion
- Jun 2010
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of agatolimod in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Aug 2006; status: completed.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00321815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321815.